Abstract
Amyotrophic lateral sclerosis (ALS) is a debilitating neuro-degenerative disorder characterized by progressive loss of motor neurons. The etiology and molecular pathogenesis of cell death in most sub-types of the disease are largely unknown. The best documented cause of moto-neuron degeneration is the mutation in the superoxide dismutase-1 (SOD1) gene, which occurs in 10% of the familial forms of ALS. Discovery of RNA interference (RNAi), which plays an important role in the regulation of gene expression, has proven to be a powerful tool to study the pathogenesis and to develop innovative treatment options for hereditary diseases, including familial variants of ALS. This review summarizes current research advances in RNAi in relation to ALS.
Keywords: Amyotrophic lateral sclerosis (ALS), gene expression, messenger RNA (mRNA), micro RNA (miRNA), RNA interference (RNAi), short (or small) hair-pin RNAs (shRNA), short (or small) interfering RNA (siRNA), superoxide dismutase (SOD), Thomas Tuschl's group, silencer RNAs
Current Drug Metabolism
Title: RNA Interference and Amyotrophic Lateral Sclerosis
Volume: 12 Issue: 7
Author(s): Albert A. Rizvanov, Sukru Gulluoglu, Mehmet E. Yalvac, Andras Palotas and Rustem R. Islamov
Affiliation:
Keywords: Amyotrophic lateral sclerosis (ALS), gene expression, messenger RNA (mRNA), micro RNA (miRNA), RNA interference (RNAi), short (or small) hair-pin RNAs (shRNA), short (or small) interfering RNA (siRNA), superoxide dismutase (SOD), Thomas Tuschl's group, silencer RNAs
Abstract: Amyotrophic lateral sclerosis (ALS) is a debilitating neuro-degenerative disorder characterized by progressive loss of motor neurons. The etiology and molecular pathogenesis of cell death in most sub-types of the disease are largely unknown. The best documented cause of moto-neuron degeneration is the mutation in the superoxide dismutase-1 (SOD1) gene, which occurs in 10% of the familial forms of ALS. Discovery of RNA interference (RNAi), which plays an important role in the regulation of gene expression, has proven to be a powerful tool to study the pathogenesis and to develop innovative treatment options for hereditary diseases, including familial variants of ALS. This review summarizes current research advances in RNAi in relation to ALS.
Export Options
About this article
Cite this article as:
A. Rizvanov Albert, Gulluoglu Sukru, E. Yalvac Mehmet, Palotas Andras and R. Islamov Rustem, RNA Interference and Amyotrophic Lateral Sclerosis, Current Drug Metabolism 2011; 12 (7) . https://dx.doi.org/10.2174/138920011796504464
DOI https://dx.doi.org/10.2174/138920011796504464 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Autoimmune Neuromuscular Disorders
Current Neuropharmacology Editorial (Thematic Issue: New Therapeutic Bearings for Repositioned Drugs)
Current Topics in Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Subject Index to Volume 1
Current Neurovascular Research Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy
Current Gene Therapy Editorial: In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets Co-Existence of GABA and Glu Transporters in the Central Nervous System
Current Topics in Medicinal Chemistry Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy